{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:16:36Z","timestamp":1792887396705,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaci.2024.07.026","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T06:39:37Z","timestamp":1723617577000},"page":"1442-1449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-1665","authenticated-orcid":false,"given":"Claus","family":"Bachert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif H.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wytske J.","family":"Fokkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gevaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Msihid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Sacks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A.","family":"Jacob-Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.07.026_bib1","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.07.026_bib2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.026_bib3","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.jaci.2018.02.002","article-title":"Identification of clinically relevant chronic rhinosinusitis endotypes using cluster analysis of mucus cytokines","volume":"141","author":"Turner","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.026_bib4","article-title":"Patients unmet needs in chronic rhinosinusitis with nasal polyps care: a patient advisory board statement of EUFOREA","volume":"2","author":"Claeys","year":"2021","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaci.2024.07.026_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2024.07.026_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4193\/Rhin17.255","article-title":"The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2024.07.026_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2024.07.026_bib8","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya","year":"2019","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2024.07.026_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2024.07.026_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.026_bib11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floch","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.07.026_bib12","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.07.026_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/JAA.S355391","article-title":"Rapid and continuing improvements in nasal symptoms with dupilumab in patients with severe CRSwNP","volume":"15","author":"Bachert","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2024.07.026_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cea.14051","article-title":"Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies","volume":"52","author":"Bachert","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.07.026_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/lary.29911","article-title":"Dupilumab in CRSwNP: responder analysis using clinically meaningful efficacy outcome thresholds","volume":"132","author":"Chuang","year":"2022","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2024.07.026_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/lary.29888","article-title":"Estimating\u00a0clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis","volume":"132","author":"Han","year":"2022","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2024.07.026_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.jaci.2024.07.026_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/alr.22944","article-title":"Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps","volume":"12","author":"Hellings","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2024.07.026_bib19","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2024.07.026_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.026_bib21","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jaip.2022.02.026","article-title":"Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases","volume":"10","author":"Canonica","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.07.026_bib22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/alr.22633","article-title":"Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a national institutes of health-sponsored workshop","volume":"10","author":"Roland","year":"2020","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924008200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924008200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T12:40:54Z","timestamp":1733316054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924008200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0091674924008200"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.07.026","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}